|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDUFA4 |
Gene summary for NDUFA4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDUFA4 | Gene ID | 4697 |
| Gene name | NDUFA4 mitochondrial complex associated | |
| Gene Alias | CI-9k | |
| Cytomap | 7p21.3 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | A0A024R9Z0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4697 | NDUFA4 | GSM4909281 | Human | Breast | IDC | 2.03e-17 | 3.34e-01 | 0.21 |
| 4697 | NDUFA4 | GSM4909282 | Human | Breast | IDC | 1.45e-17 | 3.19e-01 | -0.0288 |
| 4697 | NDUFA4 | GSM4909286 | Human | Breast | IDC | 8.67e-03 | -8.07e-02 | 0.1081 |
| 4697 | NDUFA4 | GSM4909287 | Human | Breast | IDC | 1.90e-19 | 2.57e-01 | 0.2057 |
| 4697 | NDUFA4 | GSM4909288 | Human | Breast | IDC | 7.65e-03 | -2.04e-01 | 0.0988 |
| 4697 | NDUFA4 | GSM4909289 | Human | Breast | IDC | 4.73e-05 | 2.20e-01 | 0.1064 |
| 4697 | NDUFA4 | GSM4909290 | Human | Breast | IDC | 4.15e-13 | 3.07e-01 | 0.2096 |
| 4697 | NDUFA4 | GSM4909291 | Human | Breast | IDC | 1.15e-05 | 2.58e-01 | 0.1753 |
| 4697 | NDUFA4 | GSM4909293 | Human | Breast | IDC | 2.46e-06 | -1.46e-01 | 0.1581 |
| 4697 | NDUFA4 | GSM4909294 | Human | Breast | IDC | 6.61e-27 | 1.51e-01 | 0.2022 |
| 4697 | NDUFA4 | GSM4909296 | Human | Breast | IDC | 2.56e-34 | 3.42e-01 | 0.1524 |
| 4697 | NDUFA4 | GSM4909297 | Human | Breast | IDC | 4.67e-46 | 1.50e-01 | 0.1517 |
| 4697 | NDUFA4 | GSM4909301 | Human | Breast | IDC | 5.74e-22 | 3.51e-01 | 0.1577 |
| 4697 | NDUFA4 | GSM4909302 | Human | Breast | IDC | 1.90e-08 | 1.08e-01 | 0.1545 |
| 4697 | NDUFA4 | GSM4909304 | Human | Breast | IDC | 1.18e-09 | 3.00e-01 | 0.1636 |
| 4697 | NDUFA4 | GSM4909306 | Human | Breast | IDC | 1.62e-45 | 5.01e-01 | 0.1564 |
| 4697 | NDUFA4 | GSM4909307 | Human | Breast | IDC | 7.29e-39 | 4.67e-01 | 0.1569 |
| 4697 | NDUFA4 | GSM4909308 | Human | Breast | IDC | 2.57e-55 | 5.51e-01 | 0.158 |
| 4697 | NDUFA4 | GSM4909309 | Human | Breast | IDC | 3.96e-05 | 8.67e-02 | 0.0483 |
| 4697 | NDUFA4 | GSM4909311 | Human | Breast | IDC | 3.41e-57 | -1.35e-01 | 0.1534 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000906021 | Stomach | CSG | aerobic respiration | 49/1034 | 189/18723 | 2.82e-20 | 3.12e-17 | 49 |
| GO:000609121 | Stomach | CSG | generation of precursor metabolites and energy | 83/1034 | 490/18723 | 2.95e-20 | 3.12e-17 | 83 |
| GO:004533321 | Stomach | CSG | cellular respiration | 54/1034 | 230/18723 | 4.69e-20 | 4.13e-17 | 54 |
| GO:001598021 | Stomach | CSG | energy derivation by oxidation of organic compounds | 63/1034 | 318/18723 | 4.03e-19 | 3.05e-16 | 63 |
| GO:002290021 | Stomach | CSG | electron transport chain | 41/1034 | 175/18723 | 1.66e-15 | 1.10e-12 | 41 |
| GO:001964621 | Stomach | CSG | aerobic electron transport chain | 28/1034 | 87/18723 | 9.12e-15 | 5.36e-12 | 28 |
| GO:002290421 | Stomach | CSG | respiratory electron transport chain | 31/1034 | 114/18723 | 6.18e-14 | 2.72e-11 | 31 |
| GO:004277321 | Stomach | CSG | ATP synthesis coupled electron transport | 28/1034 | 95/18723 | 1.11e-13 | 4.19e-11 | 28 |
| GO:004277521 | Stomach | CSG | mitochondrial ATP synthesis coupled electron transport | 28/1034 | 95/18723 | 1.11e-13 | 4.19e-11 | 28 |
| GO:190260021 | Stomach | CSG | proton transmembrane transport | 34/1034 | 157/18723 | 4.69e-12 | 1.55e-09 | 34 |
| GO:000612021 | Stomach | CSG | mitochondrial electron transport, NADH to ubiquinone | 17/1034 | 51/18723 | 9.01e-10 | 1.26e-07 | 17 |
| GO:004346721 | Stomach | CSG | regulation of generation of precursor metabolites and energy | 19/1034 | 130/18723 | 9.48e-05 | 2.15e-03 | 19 |
| GO:001015521 | Stomach | CSG | regulation of proton transport | 6/1034 | 24/18723 | 1.59e-03 | 1.76e-02 | 6 |
| GO:004603431 | Stomach | CAG | ATP metabolic process | 39/552 | 277/18723 | 4.41e-16 | 6.57e-13 | 39 |
| GO:001964631 | Stomach | CAG | aerobic electron transport chain | 22/552 | 87/18723 | 5.40e-15 | 6.03e-12 | 22 |
| GO:004277331 | Stomach | CAG | ATP synthesis coupled electron transport | 22/552 | 95/18723 | 3.92e-14 | 2.92e-11 | 22 |
| GO:004277531 | Stomach | CAG | mitochondrial ATP synthesis coupled electron transport | 22/552 | 95/18723 | 3.92e-14 | 2.92e-11 | 22 |
| GO:000611931 | Stomach | CAG | oxidative phosphorylation | 26/552 | 141/18723 | 6.17e-14 | 3.94e-11 | 26 |
| GO:002290031 | Stomach | CAG | electron transport chain | 28/552 | 175/18723 | 2.69e-13 | 1.50e-10 | 28 |
| GO:002290431 | Stomach | CAG | respiratory electron transport chain | 22/552 | 114/18723 | 2.06e-12 | 1.02e-09 | 22 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0493216 | Breast | Precancer | Non-alcoholic fatty liver disease | 48/684 | 155/8465 | 6.16e-17 | 1.50e-15 | 1.15e-15 | 48 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDUFA4 | insertion | Frame_Shift_Ins | novel | c.3_4insG | p.Leu2AlafsTer48 | p.L2Afs*48 | O00483 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| NDUFA4 | insertion | Frame_Shift_Ins | novel | c.1_2insGGAGGGATAGATGTGCGCTGTG | p.Met1? | p.M1? | O00483 | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | ||
| NDUFA4 | insertion | Frame_Shift_Ins | novel | c.52_53insC | p.Leu18ProfsTer32 | p.L18Pfs*32 | O00483 | protein_coding | TCGA-AR-A24S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD | ||
| NDUFA4 | SNV | Missense_Mutation | novel | c.140N>T | p.Arg47Ile | p.R47I | O00483 | protein_coding | deleterious(0) | possibly_damaging(0.476) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| NDUFA4 | SNV | Missense_Mutation | c.109N>A | p.Ala37Thr | p.A37T | O00483 | protein_coding | deleterious(0.03) | probably_damaging(0.989) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| NDUFA4 | SNV | Missense_Mutation | c.97C>A | p.Leu33Ile | p.L33I | O00483 | protein_coding | tolerated(0.16) | benign(0.005) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NDUFA4 | SNV | Missense_Mutation | novel | c.112T>G | p.Leu38Val | p.L38V | O00483 | protein_coding | tolerated(0.09) | benign(0.019) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NDUFA4 | SNV | Missense_Mutation | c.133T>C | p.Trp45Arg | p.W45R | O00483 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NDUFA4 | SNV | Missense_Mutation | novel | c.169N>A | p.Gly57Ser | p.G57S | O00483 | protein_coding | tolerated(0.35) | benign(0.253) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NDUFA4 | SNV | Missense_Mutation | novel | c.94N>C | p.Tyr32His | p.Y32H | O00483 | protein_coding | deleterious(0.04) | probably_damaging(0.913) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4697 | NDUFA4 | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
| 4697 | NDUFA4 | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL3545135 | NV-128 | |
| 4697 | NDUFA4 | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |